Brief: Innate Pharma 9-Month Revenue Up At Eur 44.3 Mln

Innate Pharma SA

14/11/2022 06:06

Nov 14 (Reuters) - Innate Pharma SA  IPH.PA :
    * INNATE PHARMA REPORTS THIRD QUARTER FINANCIAL RESULTS
    * CASH POSITION OF EUR 151.4 MILLION AS OF 30 SEPTEMBER
2022, WITH
ANTICIPATED CASH RUNWAY INTO H2 2024
    * PRELIMINARY DATA FROM ONGOING PHASE 2 TELLOMAK TRIAL OF
LACUTAMAB DEMONSTRATED CLINICAL ACTIVITY IN MYCOSIS FUNGOIDES,
PRESENTED AT EORTC-CLTG ANNUAL MEETING
    * PRELIMINARY SEZARY SYNDROME LACUTAMAB PHASE 2 DATA TO BE
PRESENTED AT ASH 2022 ANNUAL CONGRESS
    * REVENUES FOR FIRST NINE MONTHS OF 2022 AMOUNTED TO EUR
44.3
MILLION (EUR 10.3 MILLION FOR SAME PERIOD IN 2021)
    * FOR NINE-MONTH PERIOD, ENDED SEPTEMBER 30, 2022, REVENUE
FROM
COLLABORATION AND LICENSING AGREEMENTS MAINLY RESULTS FROM
SPREADING OF PAYMENTS RECEIVED UNDER OUR AGREEMENTS WITH
ASTRAZENECA AND SANOFI

Source text for Eikon:  ID:nBw3GpwjMa 
Further company coverage:  IPH.PA 
 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))